Tolerability of everolimus‐based immunosuppression in maintenance liver transplant recipients

Vallin M, Guillaud O, Morard I, Gagnieu M‐C, Mentha G, Adham M, Morelon E, Boillot O, Giostra E, Dumortier J. Tolerability of everolimus‐based immunosuppression in maintenance liver transplant recipients.
Clin Transplant 2011: 25: 660–669. © 2010 John Wiley & Sons A/S.

[1]  B. Coiffier,et al.  Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies , 2009, Leukemia & lymphoma.

[2]  F. Nevens,et al.  Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  I. Bilbao,et al.  Indications and management of everolimus after liver transplantation. , 2009, Transplantation proceedings.

[4]  E. Cordero,et al.  Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. , 2009, Transplantation proceedings.

[5]  D. Campani,et al.  The impact of everolimus on renal function in maintenance liver transplantation. , 2009, Transplantation proceedings.

[6]  G. Brock,et al.  Risk of cancer in liver transplant recipients: A look into the mirror , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[8]  M. Masetti,et al.  Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results. , 2008, Transplantation proceedings.

[9]  D. DuBay,et al.  Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low‐dose calcineurin inhibitor regimens , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  J. Trotter,et al.  Sirolimus conversion for renal preservation in liver transplantation: Not so fast , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  E. Letavernier,et al.  mToR inhibitors-induced proteinuria: mechanisms, significance, and management. , 2008, Transplantation reviews.

[12]  H. Valantine,et al.  Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. , 2007, Transplantation proceedings.

[13]  C. Ripoll,et al.  Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. , 2007, Transplantation.

[14]  N. Calvo,et al.  Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. , 2007, Transplantation proceedings.

[15]  M. Guba,et al.  Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis , 2007, Cancer and Metastasis Reviews.

[16]  G. Tenderich,et al.  Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients , 2007, Clinical transplantation.

[17]  A. Iacovoni,et al.  Possible role of everolimus in improving renal function in long-term heart transplantation. , 2007, Transplantation proceedings.

[18]  W. Chapman,et al.  Sirolimus Conversion in Liver Transplant Recipients With Renal Dysfunction: A Prospective, Randomized, Single-Center Trial , 2007, Transplantation.

[19]  P. Morel,et al.  Conversion to sirolimus‐based immunosuppression in maintenance liver transplantation patients , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  K. Olthoff,et al.  Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation , 2007, Clinical transplantation.

[21]  J. Dumortier,et al.  Negative Impact of De Novo Malignancies Rather than Alcohol Relapse on Survival After Liver Transplantation for Alcoholic Cirrhosis: A Retrospective Analysis of 305 Patients in a Single Center , 2007, The American Journal of Gastroenterology.

[22]  J. W. Fijter.  Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation , 2007 .

[23]  J. Campistol,et al.  The role of proliferation signal inhibitors in post-transplant malignancies. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  M. Abecassis,et al.  Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12‐ and 36‐month results , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  M. Mouret-Reynier,et al.  Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. , 2006, Clinical breast cancer.

[26]  C. Bodemer,et al.  Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. , 2006, Journal of the American Academy of Dermatology.

[27]  J. Wetzels,et al.  Sirolimus‐Associated Heavy Proteinuria in a Renal Transplant Recipient: Evidence for a Tubular Mechanism , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  G. Russ,et al.  Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. , 2006, Journal of the American Society of Nephrology : JASN.

[29]  G. Klintmalm,et al.  Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. , 2005, Transplantation proceedings.

[30]  B. Kahan,et al.  Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies , 2005, Transplantation.

[31]  W. Weimar,et al.  Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  V. Mabasa,et al.  The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation , 2005, Therapeutic drug monitoring.

[33]  S. Mulgaonkar,et al.  Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study , 2005, Transplantation.

[34]  T. Hannedouche,et al.  Is Sirolimus Responsible for Proteinuria , 2005 .

[35]  D. Stippel,et al.  Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. , 2005, Transplantation proceedings.

[36]  D. Henne-Bruns,et al.  Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. , 2005, Transplantation.

[37]  C. Bodemer,et al.  Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1 , 2005, Transplantation.

[38]  T. Hannedouche,et al.  IS SIROLIMUS RESPONSIBLE OF PROTEINURIA? , 2004, Transplantation proceedings.

[39]  C. Ponticelli,et al.  Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study , 2004, Transplantation.

[40]  M. Arias,et al.  Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  W. Hörl,et al.  Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[42]  Julio Pascual,et al.  Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6‐Month Safety and Efficacy Results of Two Randomized Studies , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[43]  D. Hricik,et al.  Experience with everolimus. , 2004, Transplantation proceedings.

[44]  A. Friedman,et al.  The evolving experience using everolimus in clinical transplantation. , 2004, Transplantation proceedings.

[45]  F. Schena,et al.  Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. , 2004, Journal of the American Society of Nephrology : JASN.

[46]  J. Kovarik.  Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction. , 2004, Drugs of today.

[47]  E. Schiff,et al.  Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. , 2003, Transplantation proceedings.

[48]  F. Conti,et al.  Immunosuppressive therapy in liver transplantation. , 2003, Journal of Hepatology.

[49]  D. Fine,et al.  Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[50]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[51]  E. Morelon,et al.  Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. , 2003, Transplantation proceedings.

[52]  B. Nashan.  Review of the proliferation inhibitor everolimus , 2002, Expert opinion on investigational drugs.

[53]  David A. Wohl,et al.  Not So Fast , 2002, Science.

[54]  J. Kovarik,et al.  Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. , 2002, Transplantation.

[55]  G. Zibari,et al.  End‐stage renal disease in liver transplants , 2001, Clinical transplantation.

[56]  J. Kovarik,et al.  Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. , 2001, Transplantation.

[57]  D. Davies,et al.  HISTOPATHOLOGY OF CALCINEURIN INHIBITOR‐INDUCED NEPHROTOXICITY , 2000, Transplantation.

[58]  J. Campistol,et al.  MECHANISMS OF NEPHROTOXICITY , 2000, Transplantation.

[59]  C. Bodian,et al.  Long-term medical complications in patients surviving > or = 5 years after liver transplant. , 2000, Transplantation.

[60]  L. Lumeng,et al.  Proteinuria in recipients of liver transplants. , 1996, Clinical Transplantation.

[61]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.